Aberdeen Group plc Buys 1,039,311 Shares of Moderna, Inc. $MRNA

Key Points

• Aberdeen Group increased its Moderna stake by 6,931.1% in the third quarter, buying 1,039,311 shares and ending the period with 1,054,306 shares valued at about $203 million.
• Moderna reported quarterly revenue of $1.31 billion, above the $890 million consensus estimate, and EPS of $0.38 versus expectations for a loss; revenue rose 29.2% year over year.
• Analysts’ consensus rating was Hold, with an average price target of $113.75. The article also noted that insiders sold 197,251 shares worth about $33.9 million over the prior quarter.

Aberdeen Group plc increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 6,931.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,054,306 shares of the company's stock after buying an additional 1,039,311 shares during the period. Aberdeen Group plc owned about 0.26% of Moderna worth $203,028,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in MRNA. Western Pacific Wealth Management LP bought a new stake in shares of Moderna in the 3rd quarter worth approximately $29,000. Allied Private Wealth LLC bought a new position in Moderna during the second quarter valued at $30,000. CENTRAL TRUST Co grew its holdings in Moderna by 36.5% during the third quarter. CENTRAL TRUST Co now owns 172 shares of the company's stock valued at $33,000 after purchasing an additional 46 shares during the period. Next Level Wealth Planning LLC purchased a new stake in Moderna in the third quarter worth $34,000. Finally, Archer Investment Corp purchased a new stake in Moderna in the second quarter worth $36,000. Institutional investors own 75.33% of the company's stock.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 39,145 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the sale, the president directly owned 1,636,565 shares of the company's stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 197,251 shares of company stock worth $33,875,904 over the last quarter. Corporate insiders own 10.80% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an "underweight" rating in a report on Friday, August 21st. Rothschild & Co Redburn downgraded shares of Moderna from a "neutral" rating to a "sell" rating and raised their price target for the company from $40.00 to $81.00 in a report on Thursday, September 3rd. Sanford C. Bernstein restated a "market perform" rating on shares of Moderna in a research report on Friday, September 25th. Royal Bank Of Canada restated a "sector perform" rating and set a $130.00 price target on shares of Moderna in a research report on Wednesday, August 19th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and issued a $150.00 price target (up from $60.00) on shares of Moderna in a report on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $113.75.

Latest Moderna News

These are some of the MRNA news items that stood out recently:

• Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
• Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
• Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article

Moderna Stock Performance

Moderna stock opened at $223.37 on Friday. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The firm has a market cap of $90.38 billion, a P/E ratio of -31.46 and a beta of 1.16. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $280.80. The firm has a 50-day moving average of $201.67 and a 200-day moving average of $96.41.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. Moderna's revenue was up 29.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.51) EPS. Sell-side analysts expect that Moderna, Inc. will post -5.34 EPS for the current year.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.